promed pharmacy semaglutide ProMedRx: Online GLP1 Compounding SEMA

If approved, it will be the first dual NK-1 and-3 receptor antagonist indicated for VMS in the U.S and will compete with Astellas fezolinetant (Veozah), a NK-3 antagonist FDA approved for the treatment of moderate to severe VMS

The study was funded through a research grant from Novo Nordisk to the University Medical Center Groningen

Whole-Body Wellness Options to Support Your Journey In addition to GLP-1 compounded medications, we offer a range of science-backed therapies that can complement your weight-loss journey, including Infrared Sauna, Cryotherapy and Red Light Therapy

Together, the two studies add to growing evidence that GLP-1 medications may affect biological pathways involved in aging